ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

  • Home
  • Live CE Webinar: Conquering CRAB: Exploring the Antibiotic Arsenal for the Treatment of Carbapenem-Resistant Acinetobacter baumanii Infections

Live CE Webinar: Conquering CRAB: Exploring the Antibiotic Arsenal for the Treatment of Carbapenem-Resistant Acinetobacter baumanii Infections

  • 30 Jan 2024
  • 1:00 PM - 2:00 PM (EST)

Tuesday, January 30, 2024
12:00 pm – 1:00 pm CT / 1:00 pm – 2:00 pm ET


Acinetobacter baumannii is a challenging pathogen that can lead to a wide spectrum of serious infections, including pneumonia, urinary tract infections, bloodstream infections, and skin and skin structure infections. It is a hardy opportunistic organism that can persist for prolonged periods of time in nosocomial settings and has an exquisite capacity to develop drug resistance. Carbapenem-resistant A. baumannii (CRAB) consists of a substantial portion of A. baumannii infections in the United States as well as around the world. Once carbapenem-resistance has been acquired, A. baumannii has generally acquired resistance to most other antibiotics.

This educational webinar will provide an in-depth discussion of the challenges of treating CRAB infections, including an evidence-based review of the safety and efficacy of older treatment options as well as newly approved agents. The goal of this webinar is to highlight novel therapies and the latest published evidence concerning the management of CRAB and understand how to apply these data in the real-world. Audience polling will be included throughout, with an opportunity for Q&A at the end.

Target Audience:

This activity was planned to meet the educational needs of infectious diseases and critical care pharmacists. The educational content is also relevant for physicians, and other practitioners working in infectious diseases patient-care settings who are directly involved in treatment decisions.

Learning Objectives:

  • Describe antibiotic resistance mechanisms identified in Carbapenem-Resistant Acinetobacter baumanii (CRAB) 
  • Summarize pharmacologic, pharmacokinetic, and pharmacodynamic characteristics of novel antibiotics available for treatment of infections caused by CRAB 
  • Analyze currently available literature describing the efficacy and safety of novel treatments for CRAB infections 
  • Develop an evidence-based antibiotic treatment plan for patients with CRAB infections


Michael Casias, PharmD, BCIDP, AAHIVP  
Infectious Diseases/Antimicrobial Stewardship Pharmacist
Department of Pharmacy
University of Colorado Hospital
Aurora, CO



The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0672-0000-24-001-L01-P
CPE credit: 1.0 contact hour (0.1 CEU)
Type of activity: Application
Activity Fee:  Free

To receive CE credit, participants must attend the webinar, complete online a post-test with a passing score of 70% or greater and an activity evaluation. Proof of completion will be submitted to NABP CPE Monitor.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.


This webinar is supported by an educational grant from Innoviva Specialty Therapeutics, Inc, an affiliate of Entasis Therapeutics, Inc.


In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following financial relationships have been disclosed:

  • Dr. Casias has no financial relationship with an ineligible company to disclose.
  • SIDP planners, staff and other individuals who are in a position to control the content of this CE activity have no relevant financial relationships with an ineligible company to disclose.


Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.

The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.


Society of Infectious Diseases Pharmacists •  PO Box 1488, Warrenville, IL 60555
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software